CCSA Permitting & Planning Task Subgroup

12/02/2025
11:00 (GMT)

CCSA

House keeping & Introductions

- Slides & Recording will be available for members after the meeting.
- CCSA Competition Law Policy notice is attached to the meeting invite and available on the CCSA website.
- If you are not speaking, please mute your microphone.
- Please **raise your hand** if you wish to comment, you will be invited to come off of mute, if you can also turn on your camera.
- Please also pose any **comments in the chat** and these will be picked up by the secretariat.

Q1. Do the substances in Table 1 include or cover the amines or amine derivatives that you expect will be used or emitted from your carbon capture process?

Substance	CAS number
2-amino-2-methyl-propanol (AMP)	124-68-5
2-(diethylamino)ethanol (DEELA)	100-37-8
Diethanolamine (DEA)	111-42-2
Diethylamine (DiEA) / N-Ethylethanamine	109-89-7 / 61193-06-4
Morpholine (MOR)	110-91-8
N-nitrosomorpholine (NMOR)	N/A
Piperazine (PZ)	110-85-0
Dimethylamine/N-methylmethanamine (DMA)	124-40-3
N-Methyldiethanolamine / 2-[2-hydroxyethyl(methyl)amino]ethanol (MDEA)	105-59-9
Nitrodiethanolamine/N,N-bis(2-hydroxyethyl)nitramide;nitric acid (DEA-NO2)	4185-47-1
N-nitrodiethylamine/N,N-diethylnitramide (DiEA-NO2)	7119-92-8
Dimethylnitramine/N,N-dimethylnitramide (DMA-NO2)	4164-28-7
N-nitromorpholine/4-nitromorpholine (MOR-NO2)	4164-32-3
2-methyl-2-(nitroamino)-1-propanol/N-(1-hydroxy-2-methylpropan-2-yl)nitramide (AMP-NO2)	1239666-60-4
N-nitrosopiperazine/1-nitrosopiperazine (NPz)	5632-47-3

Substance	CAS number	Proposed short-term (ST) EAL mg/m3	Proposed long-term (LT) EAL mg/m^3
2-amino-2-methyl-propanol (AMP)	124-68-5	None	0.007
2-(diethylamino)ethanol (DEELA)	100-37-8	None	0.11
Diethanolamine (DEA)	111-42-2	None	0.003
Diethylamine (DiEA) / N-Ethylethanamine	109-89-7 / 61193-06-4	0.33	0.033
Morpholine (MOR)	110-91-8	0.04	None
N-nitrosomorpholine (NMOR)	Not Applicable	0.000037	0.000005
Piperazine (PZ)	110-85-0	None	0.015

Q2. For what other amines/amine derivatives would you like to see an EAL developed?

Q3. If your organisation is likely to use or produce any of the amines in Table 2 compounds in your CCS process, do you foresee any issue in applying the EAL values in Table 2?

EAL Derivation Methodology

Q4. Do you expect **to introduce new amine or amine derivative substances** through your proposed carbon capture technology?

Q5. If so, **in the absence of insufficient toxicological data to derive an EAL by our hazard characterisation method, are you comfortable** applying one of the EAL derivation processes listed in the “Methodologies for the derivation of EALs with minimal data available” section?

Q6**. Have you any comments on the proposed alternative EAL derivation approaches** proposed in the “Methodologies for the derivation of EALs with minimal data available” section, to be applied in the absence of sufficient toxicological information?

Q7. Taking into account all the EAL derivation methods, could you provide an assessment of the level of resource implications for your company with regards to expertise and personnel?

Financial Implications

Q8. Do you have any information on the **financial implications for your company of developing new EALs?**

Q9. Do you have any information on the financial implications for your process or product of developing new EALs?

Q10. Do you have any information on the **financial implication for your company of applying the EALs levels set out in this consultation?**

Q11. Do you have any information on the financial implication for your process or product of applying the EALs levels set out in this consultation?

AOB & Conclusions

- Review actions arising from the meeting

- EAL Consultation Next Steps:
  - First draft of the CCSA response will be circulated with members for their input by the **17th of February.**
  - A second draft will be circulated for final comments.
  - Final date to submit on the **13th of March.**

- AOB